CPT code 55707 represents a transrectal ultrasound-guided prostate biopsy in which tissue is taken from standard sextant locations and from discrete ultrasound-identified lesions. This procedure is a common urologic diagnostic service used to evaluate suspected prostate cancer and guide clinical decision-making. Nationally, prostate biopsy volumes and reimbursement patterns influence access to diagnostic care, downstream pathology and oncology services, and resource utilization in ambulatory surgical centers and hospital outpatient departments. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for 55707, common sites of service, and what to expect in billing and coding workflows. The publication summarizes available national benchmarks and payer coverage landscapes when present, highlights relevant policy or coding updates that affect use of image-guided prostate biopsy codes, and situates 55707 within related urology procedure coding. This summary is intended to inform coding professionals, revenue cycle staff, and policy analysts about clinical scope, payer coverage considerations, and areas where additional documentation or coding clarity is often required. Data not available in the input.